Hôpital Beaujon
Clichy, 92110, France
NCT Number: NCT02087371
This is a prospective, multicenter, non-interventional, observational study of a cohort with a biological plasma and urine samples collection for the study of prognosis factors of cardiac complications after liver transplantation
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Clichy, 92110, France
Liver transplantation (LT) is the standard treatment for chronic or acute hepatic insufficiency with 87% of one-year survival. Cardiovascular complications are common after LT with an incidence at 6 months ranging between 25 and 50 %. These complications are associated with significant morbidity and represents the third cause of post LT mortality. Myocardial perfusion imaging or stress echocardiography, used for preoperative cardiovascular evaluation, are not enough efficient to predict the risk of post LT cardiovascular complications. However, to improve the prediction capacity of cardiovascular disease is fundamental in order to better select the candidates for LT or to develop preventive strategies. Such a strategy could reduce the morbidity and mortality from cardiovascular diseases after LT and improve the results of LT. Cardiovascular biomarkers such as troponin or natriuretic peptide are known to be predictive factors of postoperative cardiovascular complications in non cardiac surgery. The use of biomarkers in combination with conventional tests could improve the preoperative prediction of post LT cardiovascular complications.
Hypothesis: The preoperative biomarkers dosage could improve the prediction of cardiovascular complications occurring in the year after LT.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Non-inclusion criteria:
Secondary exclusion criteria:
Time frame: 1 year after liver transplantation
Identify risk factors for occurrence of cardiovascular complications in the year following the transplantation.
Cardiovascular complications include myocardial infarction, increase of cardiac troponin, cardiogenic pulmonary edema, cardiogenic shock, ventricular or supraventricular arrhythmia requiring treatment, de novo arterial hypertension and death of cardiac cause.
Time frame: 1 year after liver transplantation
Time frame: 1 year after liver transplantation
Time frame: 7 days after liver transplantation
Assistance Publique - Hôpitaux de Paris
Other
Acronym: PROCOM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03979417
Digestive System Diseases, Fibrosis
Paris, France
View Trial DetailsNCT03121521
Digestive System Diseases, Hepatopathy
View Trial DetailsNCT06944704
Digestive System Diseases, Hepatobiliary Disorders
Tanta, Egypt
View Trial DetailsNCT01988285
Digestive System Diseases, Eosinophilia
Chapel Hill, North Carolina, United States
View Trial Details